Morie Gertz
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (46)
Year:
2026
Year:
2026
Castleman disease (CD) is a heterogeneous group of lymphoproliferative disorders anatomically classified by distribution (unicentric CD [UCD], oligocentric CD [oligoCD], or multicentric CD [MCD]). Human herpes virus 8–negative MCD is called idiopathic MCD (iMCD), which includes clinical subtypes with varying phenotypes and responses: TAFRO (thrombocytopenia, anasarca, fever, renal dysfunction and/or reticulin fibrosis, and organomegaly), IPL (idiopathic plasmacytic lymphadenopathy), and not otherwise specified. OligoCD has recently emerged as an intermediate form between UCD and MCD, with unclear clinical behavior, and IPL has not been validated in a Western cohort. We retrospectively analyzed 217 patients with CD evaluated at our institution between January 2004 and August 2024. Survival probabilities were compared using log-rank tests. Overall, 57% had UCD, 20% had oligoCD, and 23% had iMCD. Patients with oligoCD and iMCD more frequently exhibited systemic symptoms than those with UCD. Patients with oligoCD and iMCD had significantly shorter event-free survival (EFS) of 8.9 and 2.3 years, respectively, than those with UCD (not reached; P< .001 and P< .02). Among iMCD subtypes, iMCD-IPL demonstrated a longer EFS than iMCD-TAFRO (P = .02), with no deaths during the follow-up periods. The results validate oligoCD and iMCD-IPL as new subtypes in this Western cohort. The survival outcome in oligoCD was intermediate between UCD and iMCD, with only a subset of patients with oligoCD requiring systemic therapy. iMCD-IPL had a favorable survival outcome in this US cohort, similar to what has been reported in non-Western countries. Tailoring treatment strategies to disease subtypes and vigilant monitoring of oligoCD for progression may improve survival outcomes in CD.
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (30)
Giampaolo Merlini
Director
University of Pavia
Esteban Braggio
Assistant Professor
Mayo Clinic
Markus Weiler
Prof. Dr
University Hospital Heidelberg
Vaishali Sanchorawala
Boston University School of Medicine
Kimon Stamatelopoulos
National and Kapodistrian University of Athens
Shaji Kumar
Medical College of Wisconsin
Saurabh Chhabra
-
David Dingli
Professor of Medicine
Mayo Clinic Minnesota
Steven Treon
Professor
Harvard Medical School
Yucai Wang
Mayo Clinic Minnesota
Marianna Fontana
University College London
Alain Delmer
Professor of Hematology
-
Yi Lisa Hwa
Program Director of Mayo Clinic Hematology NP/PA Fellowship , Associate Professor of Medicine
Mayo Clinic Rochester
Angela Dispenzieri
Professor / Consultant
Mayo Clinic Minnesota
Steven Lentz
Professor
The University of Iowa
Terri Menser
Houston Methodist
Efstathios Kastritis
Professor
National and Kapodistrian University of Athens
Anne Novak
Professor
Mayo Clinic
Ute Hegenbart
-
Anita D'Souza
Medical College of Wisconsin
Mustaqeem Siddiqui
Assistant Professor
Mayo Clinic
Divaya Bhutani
Columbia University
Adam Bledsoe
Assistant Professor of Medicine
Mayo Clinic
Giovanni Palladini
Director
Università degli Studi di Pavia
Marish I. F. J. Oerlemans
Cardiologist
Universitair Medisch Centrum Utrecht
Monique C. Minnema
-
William Hogan
Mayo Clinic Minnesota
S. Vincent Rajkumar
Professor of Medicine
Mayo Clinic Minnesota
Jorge Castillo
Clinical Director, Bing Center for Waldenstrom Macroglobulinemia
Dana-Farber Cancer Institute
Jonas Paludo
Assistant Professor of Medicine and Oncology
Mayo Clinic
Make your next move.
Prepare your application
Review drafts before you send them.